Panakès Partners

MISSION

Panakes is a venture capital firm with the ultimate goal of providing a better life to people all around the world.
We back promising teams by providing both financial and business support to build the next generation of game-changing technologies companies in the field of Life Sciences.

We invest in ambitious early stage start-ups and SMEs with innovative products globally, mainly across Europe and Israel.

We bring strong entrepreneurial and financial expertise to portfolio companies well beyond just capital, relying on a wide network of clinicians and industry experts. We have established relationships with selected industrial partners to assist our founders in accelerating their development.

We invest in people, believing that a strong and dedicated team is one of the most important factors in the success of our investments. We aim to work together with entrepreneurs to develop successful businesses as an active and well-connected investor.

We invest for people, supporting the growth of companies and people that will reshape the medical world, answering real medical needs, saving lives and providing a better quality of life for patients and care-givers.

An overall positive impact that will produce intrinsic value for both investors and society.

TEAM

Fabrizio Landi

Founder and Managing Partner

Alessio Beverina

Founder and Managing Partner

Diana Saraceni

Founder and Managing Partner

Barbara Castellano

Partner

Rob Woodman

Partner

Marco Sardina

Scientific Partner

Alessio Piuma

Principal

Andrea Ballerini

Investment Manager

Giacomo Piccinini

Investment Manager

Annalisa Coraducci

Senior Analyst

Lorenzo Giordano

CFO

Paola Crovato

Office and Deal Flow Manager

Federica Porcu

Financial Controller and ESG Manager

Michela Barcella

Network and Portfolio Talent Advisor

ADVISORS

SERGIO ABRIGNANI

Scientific Director INGM (Istituto Nazionale di Genetica Molecolare)

ANTONELLO BISCINI

Former VP Biz
Dev Diagnostic Menarini Group

PAOLA CASTAGNOLI

Scientific Director Fondazione Toscana Life Sciences

FABRIZIO CHINES

Executive Chairman & CEO SIFI

VALENTINA COGLIATI

CEO Elemaster

MAURIZIO COLOMBO

Owner & Executive VP Sapiolife

EMANUELE GATTI

Former CEO EMEA Fresenius Medical Care

MASSIMO MERCATI

CEO Aboca

SIMONE RE

CEO Digitec Innovation

LUCIO ROVATI

CEO & Chairman Rottapharm

RAFFAELE VENAFRO

Founder Crossmed

PORTFOLIO

Dermatology - Atopic Dermatitis

Surgery - Surgical Smoke Removal

Ophtalmology - presbyopia

Cardiovascular - Tricuspid Therapy

Oncology – Nuclear Medicine

Oncology - Blood Brain Barrier opening

Biotech - Age-Related Macular Degeneration

Cardiovascular - Microvascular Obstruction

In-vitro Diagnostic - Sepsis

In-Vitro Diagnostic - Alzheimer

Biotech - Oncology

Cardiovascular - Ventricular Tachycardia treatment

In-Vivo Diagnostic - Osteoporosis

Endoscopy – GI tract accessory

cardiovascual - treatment of venous thromboembolism

Biotech - respiratory diseases

Cardiovascular - Mitral Valve replacement

Cardiovascular – Lymphedema tratement

Robotic - Microsurgery

Biotech - inhalable cardiovascular treatment

Neuromodulation - Tinnitus

Biotech - Oncology vaccine

Urology - Stress Urinary Incontinence

Neuromodulation – Migraine

Oncology - Margin Assessment

Regenerative Medicine - Breast Reconstruction and Augmentation

Cardiovascular - Closure device

NEWS

BOSTON, 9 Jan, 2026

Haemonetics Acquires Vivasure Medical Limited

Munich, Germany, 8 Jan 2026

Complement Therapeutics Announces FDA Fast Track Designation for CTx001 for the Treatment of Geographic Atrophy Secondary to AMD

Cologne, Germany, 7 Jan, 2026

DISCO Pharmaceuticals Enters License Agreement to Advance Novel Cancer Surfaceome Targeted Therapies

Vedi altre

ESG

At Panakes we take the impact of our activities on the environment and on society very seriously.

Our Mission

Investing in Life Sciences technologies that improve or solve health conditions is what we do, and we are committed to doing so in a responsible and impactful way: Panakes believes that integrating these principles into our investment processes creates value for all our stakeholders.

Objectives

Environment

Verify the impact of our investment activities on climate change and energy consumption.

Social

Identify Biotech Therapies and Medical Technologies to satisfy Highly Unmet Medical Needs.

Governance

Integrate sustainability-oriented business practices into portfolio companies.

Engagement

We are UNPRI Signatory

We are part of Venture ESG community

We are part of Knowledge ESG Life Sciences Project

We are a founding member of Italian Tech Alliance

SFDR Disclosure

Managed Funds under Article 6 SFDR:
Panakes Partners oversees two Alternative Investment Funds (AIFs) classified under Article 6 of the Sustainable Finance Disclosure Regulation (SFDR), namely the Panakes Fund and the Panakes Fund Purple.

Transparency of Sustainability Risk Policies (Article 3 of EU Regulation 2019/2088):
Panakes Partners incorporates sustainability risks into the investment decision-making process by evaluating and measuring the Environmental, Social, and Governance (ESG) risks of each investee in accordance with the Risk Management Policy. The Responsible Investment Policy integrates environmental and social characteristics into various investment stages, and a dedicated investment procedure has been established for the Panakes Fund Purple. Since 2022, an annual ESG Report is made available to investors of the Panakes Fund Purple.

Transparency of Adverse Sustainability Effects at the Entity Level (Article 4 of Regulation (EU) 2019/2088):
Due to the size and early-stage nature of the portfolio companies, Panakes is not able to fully and comprehensively assess all negative sustainability impacts with reference to the indicators in Table 1 of Annex I of the Regulatory Technical Standards (RTS). Not all portfolio companies can report their negative impacts, nor is such data available from other sources. Nevertheless, Panakes partially integrates the assessment of the primary negative impacts of investment decisions on sustainability factors whenever possible using the Principal Adverse Impacts (PAIs). Panakes is committed to updating this information based on the adopted approach.

Discover more

SFDR Disclosure Statement

ESG report 2024

Responsible Investment Policy

For more detailed information on how sustainability risks are managed throughout the investment process, please refer to the SFDR Disclosure Statement and Responsible Investment Policy or contact us at info@panakes.it.

Investing in Life Sciences companies

Solving Important medical needs

Supporting entrepreneurs and scientific teams

MISSION

TEAM

Fabrizio Landi

Alessio Beverina

Diana Saraceni

Barbara Castellano

Rob Woodman

Marco Sardina

Alessio Piuma

Andrea Ballerini

Giacomo Piccinini

Annalisa Coraducci

Lorenzo Giordano

Paola Crovato

Federica Porcu

Michela Barcella

ADVISORS

SERGIO ABRIGNANI

ANTONELLO BISCINI

PAOLA CASTAGNOLI

FABRIZIO CHINES

VALENTINA COGLIATI

MAURIZIO COLOMBO

EMANUELE GATTI

MASSIMO MERCATI

SIMONE RE

LUCIO ROVATI

RAFFAELE VENAFRO

PORTFOLIO

NEWS

BOSTON, 9 Jan, 2026

Munich, Germany, 8 Jan 2026

Cologne, Germany, 7 Jan, 2026

ESG

Haemonetics Acquires Vivasure Medical Limited

Complement Therapeutics Announces FDA Fast Track Designation for CTx001 for the Treatment of Geographic Atrophy Secondary to AMD

DISCO Pharmaceuticals Enters License Agreement to Advance Novel Cancer Surfaceome Targeted Therapies

	Panakes is supported by the INNOVFIN SME Venture Capital with the financial backing of the European Union under Horizon 2020 Financial Instruments established under Regulation (No) 1291/2013 of the European Parliament and the Council establishing Horizon 2020 – the Framework Programme for Research and Innovation (2014-2020) through financial backing of the European Union under the Equity Facility for Growth established under Regulation (EU) No 1287/2013 of the European Parliament and the Council establishing a Programme for the Competitiveness of Enterprises and small and medium enterprises (COSME) (2014-2020) INFORMATIVA IN MATERIA DI TRASPARENZA DEI GESTORI DI ATTIVI DI Panakes Partners SGR S.p.A. Ai sensi dell’articolo 124-quinquies del Testo Unico della Finanza (“TUF”) Panakes Partners SGR S.p.A. non ha adottato una Politica di Impegno ai sensi dell’articolo 124-quinquies del TUF, in quanto i Regolamenti di Gestione dei FIA in gestione in linea di principio escludono gli investimenti in società con azioni ammesse alla negoziazione in un mercato regolamentato italiano o di un altro Stato membro dell’Unione europea. Inoltre, si precisa che alla data di pubblicazione di cui al presente annuncio, la SGR non ha nei portafogli degli FIA in gestione società con azioni ammesse alla negoziazione in un mercato regolamentato italiano o di un altro Stato membro dell’Unione europea. Sarà cura della SGR redigere e pubblicare una Politica di Impegno laddove in futuro se ne verificassero i presupposti.
	Disclosure pursuant to Article 3 of EU Regulation 2019/2088(policies on the integration of sustainability risks) In the scope of application of the Regulation, "sustainability risk" means an event or condition of an environmental, social, or governance nature that, upon occurrence, could cause a significant negative impact on the value of the investment. Panakès Partners SGR S.p.A. (hereinafter "Panakès") attributes particular importance to Environmental, Social and Governance (ESG) factors and intends to introduce, within its own investment and operational policies, a systematic monitoring of potential ESG risks, starting from the newly established Funds. Panakès intends to adopt a gradual fulfilment of the regulatory provisions, taking into due consideration both the current and prospective range of activity and the completion of the regulatory framework. Panakès undertakes to update the information accordingly with the approach adopted.
	Disclosure pursuant to Article 4 of REGULATION (EU) 2019/2088 (adverse sustainability impacts) Financial adviser statement of no consideration of adverse impacts on sustainability factors In the scope of application of the Regulation, "major negative impacts" means the negative effects that the investment decisions of the AIFs managed by Panakès have on sustainability factors (defined as environmental, social and employee matters, respect for human rights, anti‐corruption and anti‐bribery matters). Panakès, taking in to consideration the size, the nature, the activities of the fund currently managed, a reserved closed-end Venture Capital AIF, and its stage of life (the AIF completed its investment period in December 2020), is not in a position to consider the negative impacts on sustainability with reference at least to the indicators of table 1 of Annex I of the Regulatory Technical Standards (hereinafter "RTS"), which are still in the final approval phase. In any case, Panakès intends to gradually start the evaluation of the main negative impacts of investment decisions on sustainability factors in its processes; starting from the newly created Funds. Once the final version of the RTS will be been approved, Panakès will identify the sustainability factors to be considered in the assessment of the main negative impacts, as well as the methodology for their monitoring. Note that the Panakès employs less than 500 people and is not part of any group. Panakès undertakes to update the information accordingly with the approach adopted.